Profil bibliographique

Sarah Pasyar

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

45Publications signalées

74Citations signalées

1Affiliations récentes

Les institutions déclarées

The University of Texas MD Anderson Cancer Center

Les domaines associés

Cancer Risks and FactorsDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Les publications récentes

2026 conference-abstract OpenAlex

Distant recurrence–free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?

Jason A. Mouabbi, Akshara Singareeka Raghavendra, Taiwo Adesoye, Sarah Pasyar et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Evaluation of imiquimod treatment outcomes in vulvar melanoma.

Alyssa Osheim, Katherine Riley, Sabrina Zheng, Johana Monzon et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2026 other OpenAlex

Figure 3 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 1 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Tables 1 and 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 3 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 1 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Data from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure 1 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors

Jasmine Sukumar, Akshara Singareeka Raghavendra, Sarah Pasyar, Roland L. Bassett et autres

0 citations

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.